DaTscan is a radioactive diagnostic agent that works by binding reversibly to the human dopamine transporter (DaT) in the brain. The Food and Drug Administration (FDA) has expanded the approval of ...

Thanks to a new diagnostic imaging technique, physicians now have an objective test to evaluate patients for parkinsonian syndromes, such as Parkinson's disease. Northwestern Memorial Hospital is ...

GE Healthcare announced that DaTscan (Ioflupane I 123 Injection) is available for the detection of dopamine transporters (DaT) in the brains of adult patients with suspected Parkinsonian syndromes.

January 17, 2011 — GE Healthcare has announced Food and Drug Administration (FDA) approval of ioflupane iodine-123 injection (DaTscan), a contrast agent for use with single-photon emission computed ...

Physicians now have an objective test to evaluate patients for Parkinsonian syndromes, such as Parkinson's disease. DaTscan™ is the only FDA-approved imaging agent for assessment of movement disorders ...

Parkinson’s disease (PD), the second-most common neurodegenerative disease, is characterized by motor and nonmotor symptoms. PD is often misdiagnosed; inappropriate treatment due to misdiagnosis has ...

(RTTNews) - GE Healthcare (GE) announced on Thursday that DaTscan was approved by FDA for use in patients with suspected Dementia with Lewy Bodies or DLB. DaTscan is a radiopharmaceutical imaging ...

ST. LOUIS, April 05, 2022 (GLOBE NEWSWIRE) -- Curium announced today that its generic version of DaTscan (Ioflupane I 123 Injection) was approved on March 30, 2022, by the U.S. Food and Drug ...

The U.S. Food and Drug Administration (FDA) approved DaTscan (Ioflupane I 123 Injection), a radiopharmaceutical agent developed by GE Healthcare. DaTscan is designed to help physicians evaluate ...

This supplement to The American Journal of Managed Care summarizes proceedings from a roundtable meeting that was conducted to discuss the diagnosis of Parkinson’s disease and distinguish clinical ...